Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV)

This study has been completed.
PharmaEssentia (Co-Sponsor for USA)
Information provided by (Responsible Party):
AOP Orphan Pharmaceuticals AG Identifier:
First received: September 6, 2013
Last updated: August 2, 2016
Last verified: August 2016
Phase III study to compare the efficacy and safety of the novel monopegylated interferon alpha 2b AOP2014 versus Hydroxyurea (the current licensed therapy for this disease). One year treatment of patients with polycythemia vera. The hypothesis is that AOP2014 is superior to HU to achieve response rates measured after one year. Response is measured as normalisation of key lab parameters as well as normalized spleen size.

Condition Intervention Phase
Polycythemia Vera
Drug: Peg-P-IFN-alpha-2b (AOP2014)
Drug: Hydroxyurea
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Randomized, Open-label, Multicenter, Controlled, Parallel Arm, Phase III Study Assessing the Efficacy and Safety of AOP2014 vs. Hydroxyurea in Patients With Polycythemia Vera

Resource links provided by NLM:

Further study details as provided by AOP Orphan Pharmaceuticals AG:

Primary Outcome Measures:
  • Disease response rate [ Time Frame: Month 12 ] [ Designated as safety issue: No ]
    Disease response rate is defined as hematocrit <45% without phlebotomy (at least 3 months since last phlebotomy), platelets <400 G/L, leukocytes <10 G/L , and normal spleen size

Secondary Outcome Measures:
  • Disaese response [ Time Frame: at month 3, 6 and 9 ] [ Designated as safety issue: No ]
  • JAK2 allelic burden changes [ Time Frame: at month 6 and 12 ] [ Designated as safety issue: No ]
  • time to response [ Time Frame: from inclusion until first response confirmation ] [ Designated as safety issue: No ]
    will be measured during the study period of 12 months

  • duration of response [ Time Frame: during the 12 months of study duration ] [ Designated as safety issue: No ]
    from the first documented response on study

  • number of phlebotomies [ Time Frame: from inclusion until month 12 ] [ Designated as safety issue: No ]
  • blood parameters [ Time Frame: from inclusion until month 12 ] [ Designated as safety issue: No ]

  • spleen size [ Time Frame: at month 3, 6, 9 and 12 ] [ Designated as safety issue: No ]
    both centrally (blinded assessment) and locally

  • disease related symptoms [ Time Frame: from inclusion until month 12 ] [ Designated as safety issue: No ]

  • adverse events [ Time Frame: from inclusion until month 12 ] [ Designated as safety issue: Yes ]

  • protocol-specific adverse events of special interest [ Time Frame: from inclusion until month 12 ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 256
Study Start Date: September 2013
Study Completion Date: July 2016
Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Hydroxyurea
Hydroxyurea capsules (500 mg each). Daily intake of doses from 500 mg Q2D to 3000 mg QD
Drug: Hydroxyurea
Other Names:
  • HU
  • Hydroxycarbamide
  • brand name Litalir (or other)
Experimental: Peg-P-IFN-alpha-2b (AOP2014)
Peg-P-IFN-alpha-2b at 50mcg to max 500 mcg, given every other week as one subcutanous injection
Drug: Peg-P-IFN-alpha-2b (AOP2014)
Other Names:
  • AOP2014
  • P1101


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. 18 years or older
  2. Diagnosis of Polycythemia Vera according to the WHO 2008 criteria (Barbui et al, 2011) with the mandatory presence of JAK2V617F mutation as the major disease criterion.
  3. For previously cytoreduction untreated patients - documented need of cytoreductive treatment

    - leukocytosis (WBC>10G/L for two measurements within one week)

  4. For patients currently treated or pre-treated with HU, all of the following criteria:

    • being non responders (as defined by the response criteria for primary endpoint)
    • total HU treatment duration shorter than three years
    • no documented resistance or intolerance as defined by modified Barosi et al, 2009 criteria
  5. Hospital Anxiety and Depression Scale (HADS) score 0-7 on both subscales
  6. Patients with HADS score of 8-10 inclusive on either or both of the subscales may be eligible following psychiatric assessment that excludes clinical significance of the observed symptoms in the context of potential treatment with an interferon alpha
  7. Signed written informed consent

Exclusion Criteria:

  1. Any systematic cytoreduction for PV prior study entry with exception of HU for shorter than 3 years (see respective inclusion criterion)
  2. Any contraindication to any of the IMPs (pegylated interferon or hydroxyurea) or their excipients
  3. Any systemic exposure to a non-pegylated or pegylated interferon alpha
  4. Documented autoimmune disease at screening or in the medical history
  5. Clinically relevant pulmonary infiltrates, pneumonia, and pneumonitis at screening
  6. Systemic infections, e.g. hepatitis B, hepatitis C, or HIV at screening
  7. Known PV-related thromboembolic complications in the abdominal area (e.g. portal vein thrombosis, Budd-chiari syndrome) and/or splenectomy in the medical history
  8. Any investigational drug less than 6 weeks prior to the first dose of study drug or not recovered from effects of prior administration of any investigational agent
  9. History or presence of depression requiring treatment with antidepressant
  10. HADS score equal to or above 11 on either or both of the subscales
  11. Any risk of suicide at screening or previous suicide attempts
  12. Any significant morbidity or abnormality which may interfere with the study participation
  13. Pregnancy and breast-feeding females of reproductive potential and males not using effective means of contraception
  14. History of active substance or alcohol abuse within the last year
  15. Evidence of severe retinopathy (e.g. cytomegalovirus retinitis, macular degeneration) or clinically relevant ophthalmological disorder (due to diabetes mellitus or hypertension)
  16. Thyroid dysfunction not adequately controlled
  17. Patients tested positively with TgAb and / or TPOAb at screening
  18. History of major organ transplantation
  19. History of uncontrolled severe seizure disorder
  20. Leukocytopenia at the time of screening
  21. Thrombocytopenia at the time of screening
  22. History of malignant disease, including solid tumours and hematological malignancies (except basal cell and squamous cell carcinomas of the skin and carcinoma in situ of the cervix that have been completely excised and are considered cured) within the last 3 years
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01949805

  Show 58 Study Locations
Sponsors and Collaborators
AOP Orphan Pharmaceuticals AG
PharmaEssentia (Co-Sponsor for USA)
Principal Investigator: Heinz Gisslinger, MD Medical University of Vienna
  More Information

Responsible Party: AOP Orphan Pharmaceuticals AG Identifier: NCT01949805     History of Changes
Other Study ID Numbers: PROUD-PV  2012-005259-18 
Study First Received: September 6, 2013
Last Updated: August 2, 2016
Health Authority: Austria: Austrian Medicines and Medical Devices Agency
Bulgaria: Ministry of Health
Czech Republic: State Institute for Drug Control
France: Agence Nationale de Sécurité du Médicament et des produits de santé
Germany: Federal Institute for Drugs and Medical Devices
Hungary: Ministry of Health, Social and Family Affairs
Italy: Ministry of Health
Poland: Ministry of Health
Romania: National Agency for Medicines and Medical Devices
Russia: Ministry of Health of the Russian Federation
Slovakia: State Institute for Drug Control
Spain: Ministry of Health
Ukraine: Ministry of Health

Additional relevant MeSH terms:
Polycythemia Vera
Hematologic Diseases
Myeloproliferative Disorders
Bone Marrow Diseases
Peginterferon alfa-2b
Antineoplastic Agents
Antisickling Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs processed this record on October 21, 2016